Trial · NCT01774344
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Placebo | 237 | 95% Confidence Interval 192 | days | |
| Overall Survival (OS) | Regorafenib 160 mg (BAY73-4506) | 323 | 95% Confidence Interval 276 | days | |
| Time to Progression (TTP) | Placebo | mRECIST | 45 | 95% Confidence Interval 44 | days |
| Time to Progression (TTP) | Regorafenib 160 mg (BAY73-4506) | mRECIST | 97 | 95% Confidence Interval 87 | days |
| Time to Progression (TTP) | Placebo | RECIST 1.1 | 45 | 95% Confidence Interval 44 | days |
| Time to Progression (TTP) | Regorafenib 160 mg (BAY73-4506) | RECIST 1.1 | 119 | 95% Confidence Interval 87 | days |
| Progression Free Survival (PFS) | Placebo | mRECIST | 45 | 95% Confidence Interval 44 | days |
| Progression Free Survival (PFS) | Regorafenib 160 mg (BAY73-4506) | mRECIST | 95 | 95% Confidence Interval 86 | days |
| Progression Free Survival (PFS) | Placebo | RECIST 1.1 | 45 | 95% Confidence Interval 44 | days |
| Progression Free Survival (PFS) | Regorafenib 160 mg (BAY73-4506) | RECIST 1.1 | 102 | 95% Confidence Interval 87 | days |
| Objective Tumor Response Rate (ORR) | Placebo | mRECIST | 4.1 | percentage of subjects | |
| Objective Tumor Response Rate (ORR) | Regorafenib 160 mg (BAY73-4506) | mRECIST | 10.8 | percentage of subjects | |
| Objective Tumor Response Rate (ORR) | Placebo | RECIST 1.1 | 2.6 | percentage of subjects | |
| Objective Tumor Response Rate (ORR) | Regorafenib 160 mg (BAY73-4506) | RECIST 1.1 | 6.6 | percentage of subjects | |
| Disease Control Rate (DCR) | Placebo | mRECIST | 36.1 | percentage of subjects | |
| Disease Control Rate (DCR) | Regorafenib 160 mg (BAY73-4506) | mRECIST | 65.2 | percentage of subjects | |
| Disease Control Rate (DCR) | Placebo | RECIST 1.1 | 34.5 | percentage of subjects | |
| Disease Control Rate (DCR) | Regorafenib 160 mg (BAY73-4506) | RECIST 1.1 | 65.7 | percentage of subjects | |
| Overall Survival (OS) | Placebo | 241 | 95% Confidence Interval 196 | days | |
| Overall Survival (OS) | Regorafenib 160 mg (BAY73-4506) | 326 | 95% Confidence Interval 278 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01774344/results